Viskase Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Viskase Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $26.0K | Mar 2, 2026 |
| FY2023 | Dec 31, 2022 | $26.0K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $701.0K | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $52.0K | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $207.0K | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $6.92M | Feb 19, 2020 |
| FY2018 | Jun 30, 2018 | $60.0K | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $8.38M | Feb 21, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $8.38M | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | $8.38M | Mar 21, 2018 |
| FY2016 | Dec 31, 2015 | $17.46M | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $31.17M | Mar 21, 2016 |
| FY2013 | Dec 31, 2013 | $7.43M | Mar 14, 2014 |
| FY2013 | Sep 30, 2013 | $8.83M | Mar 14, 2014 |
| FY2013 | Jun 30, 2013 | $8.06M | Mar 14, 2014 |
| FY2013 | Mar 31, 2013 | $10.18M | Mar 14, 2014 |
| FY2013 | Dec 31, 2012 | $10.65M | Mar 14, 2014 |
| FY2013 | Sep 30, 2012 | $11.12M | Mar 14, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.41M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $778.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.37M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($186.0K) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($469.0K) | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | ($1.31M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($979.0K) | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $5.85M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $5.45M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($1.13M) | Mar 21, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.31M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.33M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($1.04M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($1.03M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($469.0K) | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | ($1.31M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($973.0K) | Feb 23, 2021 |
| FY2015 | Dec 31, 2015 | $10.80M | Mar 21, 2016 |
| FY2015 | Dec 31, 2014 | $28.79M | Mar 21, 2016 |
| FY2014 | Dec 31, 2013 | $18.16M | Mar 5, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $0 | Mar 5, 2015 |
| FY2014 | Dec 31, 2013 | $2.72M | Mar 5, 2015 |
| FY2013 | Dec 31, 2012 | $20.89M | Mar 14, 2014 |
| FY2013 | Dec 31, 2011 | $40.18M | Mar 14, 2014 |
| FY2012 | Dec 31, 2010 | $49.88M | Mar 18, 2013 |
| FY2011 | Dec 31, 2009 | $45.64M | Mar 12, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.01M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.12M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.31M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($659.0K) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($501.0K) | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | ($380.0K) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $6.91M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | ($978.0K) | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $6.47M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $2.60M | Mar 21, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 14, 2014 |
| FY2012 | Dec 31, 2012 | $23.0K | Mar 18, 2013 |
| FY2011 | Dec 31, 2011 | $630.0K | Mar 12, 2012 |
| FY2011 | Dec 31, 2010 | $1.97M | Mar 12, 2012 |
| FY2011 | Dec 31, 2009 | $1.99M | Mar 12, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.81M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $47.17M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $47.70M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $47.59M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $47.75M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $48.23M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $6.48M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $15.51M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $9.51M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $11.27M | Mar 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $4.80M | Mar 21, 2016 |
| FY2015 | Dec 31, 2014 | $5.44M | Mar 21, 2016 |
| FY2014 | Dec 31, 2013 | $1.87M | Mar 5, 2015 |
| FY2013 | Dec 31, 2012 | $122.31M | Mar 14, 2014 |
| FY2012 | Dec 31, 2011 | $146.03M | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $157.00M | Mar 12, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.53M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.01M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($3.51M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $3.41M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $4.87M | Mar 20, 2024 |
| FY2022 | Dec 31, 2020 | $7.36M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $6.06M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $14.99M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $9.14M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $10.33M | Feb 21, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($73.30M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($69.89M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($70.67M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($72.04M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($71.86M) | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | ($71.39M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($70.08M) | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | ($69.10M) | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | ($74.95M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($80.39M) | Mar 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.57M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $46.86M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $47.01M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $46.98M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $47.64M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $48.14M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.45M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $6.50M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $7.48M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $7.64M | Feb 21, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 25, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 21, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 21, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 25, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Mar 21, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 21, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 21, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.21M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 74.21M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 74.21M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 74.21M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 74.21M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 74.21M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 44.21M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | 44.21M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 44.21M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 44.21M | Mar 21, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.28M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.28M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.28M | Feb 21, 2025 |
| FY2021 | Dec 31, 2021 | $0 | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $7.96M | Feb 23, 2021 |
| FY2020 | Oct 15, 2019 | $5.31M | Feb 23, 2021 |
| FY2020 | Mar 21, 2019 | $2.65M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $6.63M | Feb 21, 2019 |